Medical research stocks took a bath Thursday, led by BillionToOne's (BLLN) second-quarter report, featuring a widespread beat but no guidance raise. The company is a victim of its own success, said William Blair analyst Matt Larew. Up until the close on Wednesday, BillionToOne stock had climbed more than 84% since putting out its first-quarter report on May 6. "Both the…
Why BillionToOne Plummeted 36%, Leading A Medtech Sell-Off
Kaynak: Yahoo Finance
İlgili Haberler
Global
Cathie Wood's Ark Invest Makes SpaceX, Circle Top Holdings After Latest Buying Spree
Yahoo Finance · 20 dk önce
Global
Figma's CTO Sells 261,000 Shares for $6.6 Million. Here's What That Means for Investors.
Yahoo Finance · 21 dk önce
Global
Mark Zuckerberg's Net Worth Dropped $18 Billion in a Single Day as Meta Stock Extended a Losing Streak. Is the Sell-Off Overdone?
Yahoo Finance · 21 dk önce
Global
Joby Aviation Climbs 9% on Raised Guidance as Archer Aviation, EHang Sit Out the eVTOL Rally
Yahoo Finance · 25 dk önce
Global
Chegg, Inc. Q2 2026 Earnings Call Summary
Yahoo Finance · 32 dk önce
Yorumlar (0)
Giriş yaparak yorum yazabilirsin.
İlk yorumu sen yaz.